Virginia King received treatment for metastatic breast cancer at a hospital in Santa Fe, N.M., where she was billed $22,700 for a drug that cost $2,700. The hospital was part of a federal program allowing it to profit from the price difference. Apexus, a company managing the program, has been accused of maximizing profits and cashing in on the program’s growth, leading to increased health care costs.
Full Article
Why NovoCure Stock Was Withering on Wednesday
Cancer-focused biotech NovoCure (NVCR -4.07%) saw its stock price target cut by Wedbush analyst David Nierengarten from $29 to $27, leading to a nearly 5% drop in stock value amidst bearish sentiment. Despite a 21% year-over-year revenue growth in Q4 2024, the company reported a net loss of $0.61 per share, worse than analysts expected. While investors are impatient for positive news, the company remains well-positioned in cancer treatment, suggesting it may be a discount...
Read more